Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study

This case series and propensity-matched cohort study on the use of tigecycline in Clostridioides difficile infection (CDI) evaluated the effect of tigecycline on 30-day mortality. Adjusted for ATLAS Score, hypotension, treatment time period, and serum lactate, tigecycline did not significantly impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Emma C., Warren, Cirle A., Ma, Jennie Z., Madden, Gregory R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211400/
https://www.ncbi.nlm.nih.gov/pubmed/35647645
http://dx.doi.org/10.1128/aac.00001-22
_version_ 1784730356905148416
author Phillips, Emma C.
Warren, Cirle A.
Ma, Jennie Z.
Madden, Gregory R.
author_facet Phillips, Emma C.
Warren, Cirle A.
Ma, Jennie Z.
Madden, Gregory R.
author_sort Phillips, Emma C.
collection PubMed
description This case series and propensity-matched cohort study on the use of tigecycline in Clostridioides difficile infection (CDI) evaluated the effect of tigecycline on 30-day mortality. Adjusted for ATLAS Score, hypotension, treatment time period, and serum lactate, tigecycline did not significantly improve 30-day mortality (odds ratio: 0.89; 95% confidence interval: 0.25–3.12; P = 0.853). A randomized controlled trial is needed to determine efficacy and safety of tigecycline in severe or refractory CDI.
format Online
Article
Text
id pubmed-9211400
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-92114002022-06-22 Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study Phillips, Emma C. Warren, Cirle A. Ma, Jennie Z. Madden, Gregory R. Antimicrob Agents Chemother Clinical Therapeutics This case series and propensity-matched cohort study on the use of tigecycline in Clostridioides difficile infection (CDI) evaluated the effect of tigecycline on 30-day mortality. Adjusted for ATLAS Score, hypotension, treatment time period, and serum lactate, tigecycline did not significantly improve 30-day mortality (odds ratio: 0.89; 95% confidence interval: 0.25–3.12; P = 0.853). A randomized controlled trial is needed to determine efficacy and safety of tigecycline in severe or refractory CDI. American Society for Microbiology 2022-06-01 /pmc/articles/PMC9211400/ /pubmed/35647645 http://dx.doi.org/10.1128/aac.00001-22 Text en Copyright © 2022 Phillips et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Therapeutics
Phillips, Emma C.
Warren, Cirle A.
Ma, Jennie Z.
Madden, Gregory R.
Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study
title Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study
title_full Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study
title_fullStr Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study
title_full_unstemmed Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study
title_short Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study
title_sort impact of tigecycline on c. difficile outcomes: case series and propensity-matched retrospective study
topic Clinical Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211400/
https://www.ncbi.nlm.nih.gov/pubmed/35647645
http://dx.doi.org/10.1128/aac.00001-22
work_keys_str_mv AT phillipsemmac impactoftigecyclineoncdifficileoutcomescaseseriesandpropensitymatchedretrospectivestudy
AT warrencirlea impactoftigecyclineoncdifficileoutcomescaseseriesandpropensitymatchedretrospectivestudy
AT majenniez impactoftigecyclineoncdifficileoutcomescaseseriesandpropensitymatchedretrospectivestudy
AT maddengregoryr impactoftigecyclineoncdifficileoutcomescaseseriesandpropensitymatchedretrospectivestudy

Ejemplares similares